| Biomarker ID | 1474 |
| PMID | 25075204 |
| Year | 2014 |
| Biomarker | SMAD4 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.48 |
| Effect on Pathways | Pathways include: Cell cycle: G1/S checkpoint, NF-kappaB activation by non-typeable Hemophilus influenzae, TGF-beta receptor activation of SMADs, Heart development, CTCF pathway |
| Experiment | Lethal Outcome Vs No Lethal Outcome |
| Type of Biomarker | Prognostic |
| Cohort | 340 Prosteactomy samples were chosen in the cohort and divided into training and testing |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0035 |
| Method Used | Automated quantitative multiplex immunofluorescence in situ imaging |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |